z-logo
open-access-imgOpen Access
The outcome of platelet-rich plasma injection therapy in chronic plantar fasciitis
Author(s) -
O. P. Pandey,
Sunil Kumar Kirar,
Atul Varshney,
Sharanjeet Singh,
Hod
Publication year - 2021
Publication title -
international journal of medical research and review
Language(s) - English
Resource type - Journals
eISSN - 2321-127X
pISSN - 2320-8686
DOI - 10.17511/ijmrr.2021.i02.09
Subject(s) - plantar fasciitis , medicine , platelet rich plasma , visual analogue scale , surgery , complication , fasciitis , physical therapy , heel , platelet , anatomy
Background: Plantar Fasciitis is a frequently encountered problem in the everyday practice oforthopaedics. Treatment of Plantar Fasciitis is challenging to treating surgeon. Various conservativenon-invasive treatment modalities are available like rest, casting, night splinting, NSAIDs. Ifconservative management fails then corticosteroid injection over the medial tuberosity of calcaneumis an effective treatment. But in recent years Platelet-rich plasma (PRP) has proved to be a safealternative approach with less complication. This study aims to find out the effectiveness of PRPinjections in Plantar Fasciitis. Material and Method: In this study, 60 patients with Plantar Fasciitiswere included. Regular follow up was done at an interval of 4 weeks, 8 weeks and 6 months afterPRP injection. Pain intensity was measured before and after injection on every follow up using theVisual Analogue Scale (VAS). Patients who have undergone at least 4 weeks of conservativetreatment were included in the study. Results: After analysis of data, the average VAS score beforeinjection was 7.01±1.35. Whereas at the end of the last visit (i.e. 6 months) average VAS scorereduced to 2.2±1.25. This difference was statistically significant (ANNOVA test p <0.0001).Conclusion: we concluded that injection of PRP is a safe, convenient and effective approach to treatchronic Plantar Fasciitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here